Dosing Impact on Clinical Outcomes (Analyzed as parallel-group)
depression
SECONDARY, EMA
Secondary analyses will also test dosing effects of mbNF (15-min versus 30-min condition) on change in clinical outcomes from pre- to post-mbNF as follows:
Secondary analyses each involve tests of 7 outcome measures (EMA reports of depression (1) and rumination (2) the week following mbNF; EMA reports of depression (3) and rumination (4) the week of the 1-month follow-up, and CDRS-R (5), MFQ (6), and RRS brooding subscale (7) at 1-month follow-up. For EMA analyses, participants with ≥ 5 responses will be included. Given 4 tests for depression symptom outcomes and 3 tests for rumination outcomes for secondary analyses respectively, the Benjamini–Hochberg procedure will be used to control the false discovery rate at an alpha level of 0.05 [